IPP Bureau
Nitinotes secures CE mark for automated suturing platform ‘EndoZip’
By IPP Bureau - November 11, 2025
Enabling a new era in minimally invasive obesity treatment across Europe
Granules Life Sciences receives first FDA approval for Hyderabad facility
By IPP Bureau - November 11, 2025
Gilead’s Trodelvy falls short on progression-free survival in key breast cancer trial
By IPP Bureau - November 10, 2025
While the trial fell short of demonstrating a statistically significant PFS benefit compared to chemotherapy, early data suggest a potential overall survival advantage
AstraZeneca delivers double-digit growth
By IPP Bureau - November 10, 2025
The pharma giant's 11% rise in total revenue to $43.2 billion highlights consistent execution of its growth strategy
SOUKYA launches Rs. 125 crore, 100-bed AYUSH hospital in Bengaluru
By IPP Bureau - November 10, 2025
The upcoming facility marks a strategic milestone in SOUKYA’s mission to make evidence-based holistic healthcare
Johnson & Johnson gets FDA nod for new depression treatment
By IPP Bureau - November 10, 2025
This approval is based on positive results from two Phase 3, global, double-blind, placebo-controlled trials
Zydus Lifesciences posts Q2 FY26 PAT at Rs. 1,258.6 Cr
By IPP Bureau - November 10, 2025
Organic capex during the quarter amounted to Rs. 491.1 crore, supporting ongoing business expansion initiatives
Touchlight unveils next-gen circular DNA portfolio for advanced gene therapies
By IPP Bureau - November 10, 2025
The expanded mbDNA portfolio delivers enhanced stability, reduced immunogenicity, and broad compatibility with gene insertion and expression technologies
Bristol Myers Squibb prices €5 billion senior unsecured notes offering
By IPP Bureau - November 10, 2025
The offering is expected to close on November 10, 2025, subject to customary closing conditions
Relmada gains FDA backing for two registrational trials and reports 92% response with NDV-01 in bladder Cancer
By IPP Bureau - November 10, 2025
Relmada expects to initiate its Phase 3 program in the first half of 2026
Venus Remedies expands ASEAN presence with new drug approvals in Vietnam
By IPP Bureau - November 10, 2025
Venus Remedies now has 29 active product approvals in Vietnam alone
Biohaven disappointed as rare disease therapy faces FDA setback 'despite promising results'
By IPP Bureau - November 10, 2025
The FDA setback highlights ongoing tensions between patient needs, regulatory processes, and the use of real-world evidence in evaluating treatments for rare diseases
Novo Nordisk India partners with Emcure to commercialise Poviztra in India
By IPP Bureau - November 10, 2025
Poviztra is a second brand of Wegovy
Glenmark secures China approval for Ryaltris
By IPP Bureau - November 10, 2025
The approval granted with zero supplementation requests is an important milestone in Glenmark’s respiratory pipeline
Marksans Pharma's Goa unit clears FDA inspection
By IPP Bureau - November 10, 2025
The said inspection concluded with Zero Form 483 observation
